Clay Siegal founded one of the fast-growing biotech firms

At the heart of Cascade Business Park lies the future of Seattle’s biotech community; Seattle Genetics. The company was founded in the year 1998 and ever since, it has been on its toes researching, testing, and packaging medicinal drugs. Outside the compound, there is a big human antibody sculpture made of Lego bricks. This is not just any model you would like to use for beauty purposes. No. What you may not know is that it is the symbol of what makes Seattle Genetics different from the rest.

Human antibodies are embedded deep in the heart of this company. They devised a way of using antibodies to deliver toxic substances into cancerous cells to kill them from inside.

This method is what could potentially map Seattle Genetics as one of the top biotech firms in the world. Perhaps its market value of over $10 billion and employees of over 900 can be justified by this fact. In fact, it is ranking among the top biotech firms in Washington.

Seattle Genetics boasts of Adcetris as their flagship drug. This particular drug is used to treat cancer that affects lymphatic system commonly known as Hodgkin lymphoma. The drug is still under research.

The company is shifting its focus to not developing new drugs but also taking over the international marketing of their drugs. This is the opposite of what they did before; partnered with Takeda Oncology to handle its international commercialization. CEO Mr. Siegal recently opened a new office in Switzerland to facilitate its international marketing.

Seattle Genetics is unstoppable. In 2016, its total revenue was around $418 million not to mention the stock price which increased by 46 percent from 2014.

The company trusts it, researchers. This is seen in an investment of over $376 million which is a 64 percent increase when compared to 2014 spending.

Such spending is directed mostly to a drug known as antibody-drug conjugate or (ADC). The drug targets antigens and functions by attaching themselves to cancer cells and deliver toxin into the cells to kill them. The scientists refer to it as ‘smart bomb.’ The positive thing about this drug is that it functions without causing harm to other healthy cells.

Besides the ADC, there are other 11 drugs in Seattle Genetics’ pipeline, but CEO Siegal believes four of them possess great potential. The drugs include; Adcetris used for Hodgkin lymphoma, 33A used to treat acute myeloid leukemia, 22ME aimed for urothelial cancer including bladder cancer, and LIV1 aimed at treating breast cancer.

About Clay Siegal

Dr. Clay Siegal is the founder and CEO of Seattle Genetics. He went to the University of Maryland where he received his undergraduate degree and later a doctorate from the George Washington University. Dr. Siegal has an extensive experience of over 20 years in cancer research as well as therapeutic drug manufacture.

Dr. Siegal is an exemplary entrepreneur who has defied all the odds to emerge successfully.

Robert Ivy, Making Strides In Architecture

Robert Ivy is an important figure in the field of architecture, and has had a long, successful career. He has made strides in the publishing industry and has contributed much to the field with his position in the American Institute of Architects (AIA).

Before entering the field and moving his way up the leadership ladder, Ivy earned a Bachelor of Arts from Sewanee: The University of the South and then a Masters of Architecture from Tulane University. One of his earlier career accomplishments includes becoming Editor in Chief of the magazine Architectural Record.

While editor in chief, he was responsible for the publication growing to become the world’s most widely circulated architectural journals. While there, he supervised the production of a number of physical and digital publications. Thanks to his leadership, the magazine won numerous awards which include 26 Jesse H. Neal awards for magazine journalism, The National Magazine Award for General Excellence, a 2008 MPA Digital Design Award for Website of the Year and 7 Ozzies: Folio Design Awards. Ivy’s career involves other forays into publishing as well. In 2001, the biography that he authored, “Fay Jones: Architect” was published and is currently in its third edition. The book details the work of famed architect Frank Lloyd Wright. In addition, Ivy served as vice president and editorial director of McGraw-Hill Construction.

In 2011, Ivy was named Chief Executive Officer of the AIA. Since assuming the role, Ivy has done much for the organization in terms of revolutionizing the way the organization serves the profession of architecture. For one, he spearheaded investigations into the roles that architects have in society along with the future of architecture. Ivy also helped launch a pioneering digital technology infrastructure along with spreading public awareness. Ivy made a commitment to a decade long effort to use design as a way to improve public well being with the use of grants, community planning and digital programs. Ivy has used AIA resources to address the issues that matter the most, such as climate change and sustainability in architecture.

Ivy’s accomplishments do not stop there. In 2009, he was a recipient for the G.D Crain award. He was also named “Master Architect” in 2010 by Alpha Ro Chi. He is the only architect to be selected for the award in the 21st century. While he has accomplished much in his career thus far, there is much more that he plans to do for the world of architecture.

Like Robert Ivy on Facebook

There is More That Needs to be Done on the Data-Centric Approach towards Cancer

Keeping in mind the end goal to treat cancer effectively, specialists require information and the needed data is about various items. That is what is lacking from today’s therapeutic research framework, as per Eric Lefkofsky, prime supporter and CEO of Tempus, a startup with the objective to build up databases and fine-tune treatment of cancer. There’s no deficiency of patient information out there, however there is an absence of sources that join both genomic data with remedial information, Mr Lefkofsky clarified in San Diego at the Fortune Brainstorm Health meeting.

“Combining of molecular information is one factor; however you additionally require clinical information. You require remedial and result reaction information,” Lefkofsky noted. That implies besides data regarding a patient’s DNA & RNA makeup, clinicians likewise ought to know which they apply and how their outcomes.

For instance, if a specialist is taking a gander at a team of cancer patients receiving Herceptin, they should know the reason it works on 40% and not 60%. Could there be anything else happening with patients not receiving help? Are they receiving other drugs or even diabetic? Those are some of the questions doctors need to clarify. The given information ought also to flow freely between clinicians and researchers among other involved specialists.

Eric Lefkofsky is the CEO and co-founder of Tempus, an innovation organization that has established an operating system to help in battling cancer. He is an establishing accomplice of Lightbank, a venture fund investment dealing with disruptive technologies. Eric is likewise the chairman and co-founder of Groupon, a world e-commerce marketplace. He also co-founded Uptake Technologies which is a key prescient analytics platform for the globe’s biggest industries; Mediaocean, a main supplier of incorporated media obtainment innovation; Echo Global Logistics, an innovation empowered logistics & transportation outsourcing company; and InnerWorkings, a worldwide supplier of promotional solutions and managed print.

In 2006 Eric Lefkofsky set up the Lefkofsky Family Foundation, which is an independent charitable establishment, together with his wife liz to develop high-effect activities that improve lives in the society served. Lefkofsky is a graduate of Michigan University and University of Michigan Law School.

http://chicagoinno.streetwise.co/2016/07/22/eric-lefkofskys-next-move-curing-cancer-at-tempus/